Literature DB >> 25345369

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment.

M Cugno1, S Tedeschi, G Ardissino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25345369     DOI： 10.1111/jth.12764

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  5 in total

1.  Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.

Authors:  Gianluigi Ardissino; Francesca Tel; Martina Sgarbanti; Donata Cresseri; Antenore Giussani; Samantha Griffini; Elena Grovetto; Ilaria Possenti; Michela Perrone; Sara Testa; Fabio Paglialonga; Piergiorgio Messa; Massimo Cugno
Journal:  Pediatr Nephrol       Date:  2017-10-18       Impact factor: 3.714

2.  Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels.

Authors:  Massimo Cugno; Valentina Capone; Samantha Griffini; Elena Grovetti; Giulia Pintarelli; Luigi Porcaro; Emilio Clementi; Gianluigi Ardissino
Journal:  J Nephrol       Date:  2022-01-11       Impact factor: 3.902

Review 3.  A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome.

Authors:  Borja Quiroga; Alberto de Lorenzo; Cristina Vega; Fernando de Alvaro
Journal:  Am J Case Rep       Date:  2016-12-15

Review 4.  Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Authors:  Kioa Lente Wijnsma; Rob Ter Heine; Dirk Jan A R Moes; Saskia Langemeijer; Saskia E M Schols; Elena B Volokhina; Lambertus P van den Heuvel; Jack F M Wetzels; Nicole C A J van de Kar; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 5.  Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Authors:  Kioa L Wijnsma; Caroline Duineveld; Jack F M Wetzels; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2018-11-06       Impact factor: 3.714
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.